Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-869 · 1 trial · 1 indication
Blood samples for the PK of ABT-869 and ketoconazole will be collected at designated time points throughout the study.
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ABT-869 | DRUG | 2.5mg \[5 mg days 1, 8 and 12. 17.5 mg on days 13 and after\] |
| ketoconazole | DRUG | 400 mg days 6-11 |
Inclusion Criteria 1. Male or female and age is \>= 18 years. 2. Must have a histologically or cytologically confirmed non-hematologic malignancy. 3. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-2. 4. Must have adequate bone marrow, renal and hepatic function as follows: * B...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ABT-869, also known as linifanib, is an investigational small molecule being studied for the treatment of solid tumors. It is in Phase 1 clinical development for oncology indications. The drug is not yet approved and remains under investigation.
ABT-869 is being developed by Abbott Laboratories, a company traded under the ticker ABT. The drug is an investigational small molecule in Phase 1 clinical development for solid tumors.
ABT-869 is in Phase 1 clinical development. It is an investigational drug for solid tumors and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
ABT-869 has one completed Phase 1 trial, NCT01114191, which assessed the effect of ketoconazole on the pharmacokinetics of linifanib (ABT-869) in 12 participants with solid tumors in the United States.
Yes, ABT-869 is also known as linifanib. The drug is an investigational small molecule being developed by Abbott Laboratories for the treatment of solid tumors and is currently in Phase 1 clinical development.